The Discounted Cash Flow (DCF) valuation of Marinus Pharmaceuticals Inc (MRNS) is (96.03) USD. With the latest stock price at 0.55 USD, the upside of Marinus Pharmaceuticals Inc based on DCF is -17560.7%.
Based on the latest price of 0.55 USD and our DCF valuation, Marinus Pharmaceuticals Inc (MRNS) is a sell. selling MRNS stocks now will result in a potential gain of 17560.7%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.4% - 6.2% | 5.8% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (425.43) - (55.82) | (96.03) |
| Upside | -77451.7% - -10248.4% | -17560.7% |